DeckTherapeutics obtains exclusive license to omega-3 IPR from DSM Nutrition
DeckTherapeutics today announced that the company has signed a letter of intent towards a exclusive intellectual property licensing agreements with the DSM Nutrition. The agreement provides access for DeckTherapeutics to use a proprietary process for manufacturing of novel semi-synthetic omega-3 glycerides towards development of novel intravenous omega-3 fatty acid emulsions